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Abstract
Background: Dengue virus infection (DVI) is a prevalent and potentially fatal viral disease associated with
coagulopathy. So far, the coagulation profile of DVI patients with thrombocytopenia has not been assessed through
a viscoelastic test such as rotational thromboelastometry. We aimed to describe the prevalence and characteristics
of coagulation abnormalities in dengue fever outpatients with thrombocytopenia, addressed by both rotational
thromboelastometry and conventional coagulation tests.
Methods: This was a cross-sectional study conducted between April 6th and May 5th 2015 in São Paulo, Brazil
during a dengue outbreak. Thromboelastometry (ROTEM®) and the conventional coagulation tests prothrombin
time (PT), international normalized ratio (INR), activated partial thromboplastin time (aPTT), thrombin time (TT),
platelet count and fibrinogen levels were performed in 53 patients with DVI and thrombocytopenia.
Results: Despite a median interquartile range (IQR) platelet count of 77 (63–88) x 109/L in DVI patients,
conventional coagulation tests and plasma fibrinogen levels were within the normal range. Subjects demonstrated
hypocoagulability in 71.7% (38/53) in INTEM and 54.7% (29/53) in EXTEM DVI patients. FIBTEM analyses detected
only 5.7% (3/53) with hypocoagulability among this population. The median (IQR) clotting time (CT), clot formation
time (CFT) and maximum clot firmness (MCF) on INTEM were, respectively, 177 (160–207) sec, 144 (108–178) sec
and 48 (42–52) mm. On EXTEM, median (IQR) CT, CFT and MCF were, respectively, 69 (65–78) sec, 148 (126–198) sec
and 49 (44–55) mm. Median (IQR) MCF on FIBTEM was 15 (13–18) mm.
Conclusion: Thromboelastometry impairment is highly prevalent in DVI patients with thrombocytopenia,
particularly in INTEM and EXTEM analyses, while standard coagulation tests are normal in this setting. Clinical
implications remain to be established.
Background
Dengue is by far the most incident human arbovirus dis-
ease [1], with over 2.5 billion people living in high-risk
transmission areas [2]. The World Health Organization
(WHO) estimates 50–100 million of dengue virus infec-
tions (DVI) per year, resulting in 500,000 hospitalizations
and 20,000 deaths worldwide [1, 2].
Dengue hemorrhagic fever (DHF) represents a se-
vere clinical presentation of DVI and is characterized
by the presence of varying degrees of hemostatic dis-
orders [3, 4]. Intense and amplified cytokine release,
along with the complement activation, result in endo-
thelial dysfunction, platelet destruction and consump-
tion of coagulation factors, which may lead to a life
threatening disseminate intravascular coagulation
(DIC) [5, 6]. Indeed, blood coagulation disorders are
commonly observed in patients with DHF and dengue
shock syndrome [6, 7].
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Many studies have assessed the coagulation system in
DVI through conventional coagulation tests such as the
prothrombin time (PT), international normalized ratio
(INR), thrombin time (TT), and activated partial
thromboplastin time (aPTT) [3, 6, 8, 9]. Nevertheless,
conventional coagulation tests were validated to monitor
vitamin K antagonists and heparin therapy [10, 11]. Al-
though conventional coagulation tests have not been val-
idated to predict and/or to guide therapy in acute
(acquired) hemorrhage, they have been widely used for
this purpose [10]. Conventional coagulation tests results
may take a few hours to be completed and reported,
they track the complexity of hemostatic impairment
poorly, and most frequently, they reflect late coagulopa-
thy disorders [10–13].
Rotational thromboelastometry (ROTEM®) is a point
of care test that promptly provides (5–30 min) infor-
mation about the dynamics of clot formation,
stabilization and dissolution, reflecting the in vivo
hemostasis at the bedside [12]. ROTEM provides
more clinically useful and reliable information than
the conventional coagulation tests in critically ill pa-
tients [13, 14], yielding a graphical presentation of fi-
brin polymerization process, involving fibrinogen and
platelet function, and fibrinolysis [13].
To our knowledge, no study has evaluated the coagu-
lation profile of patients with DVI with rotational
thromboelastometry. Therefore, we aimed at describing
the prevalence of coagulation abnormalities addressed
by both thromboelastometry and conventional coagula-
tion tests in cases of dengue fever outpatients with
thrombocytopenia. Additionally, we evaluated the correl-
ation between conventional coagulation tests and throm-
boelastometry in this population of patients.
Methods
Study design and setting
This was a cross-sectional study conducted during a
DVI outbreak in São Paulo, Brazil between April 6th and
May 5th 2015. This study was approved by the University
of São Paulo Institutional Review Board [Comissão de
Ética para Análise de Projetos e Pesquisas (CAPPesq),
approval number: 0652/09]. All patients provided in-
formed consent prior inclusion in this study.
Participants
Patients were screened at an outpatient clinic established
in a neighborhood in the city of São Paulo with high in-
cidence of DVI. Patients with at least 24 h of fever (axil-
lary temperature >37.8 °C), in addition to a positive
dengue virus (DV) specific immunoglobulin IgM/IgG or
non-structural protein-1 (NS1) antigen rapid test (DEN-
GUE DUO Bioeasy®, Kyonggi-Do, South Korea) and
platelet count <100 x 109/L were consecutively included
in this study (Fig. 1).
Exclusion criteria included pregnancy, presence of on-
cologic or hematologic disorders, solid or bone marrow
transplantation, secondary thrombocytopenia, previous
known coagulopathy, chronic hepatitis B or C, chronic
renal failure and use of anti-platelet therapy or vitamin
K antagonists.
Dengue virus infections triage, support and blood
sampling
All patients who visited the outpatient clinic had their
clinical history taken to obtain information on length of
time, type and severity of symptoms and vital signs ana-
lysis (arterial blood pressure, axillary temperature and
heart rate) (Fig. 2). Demographic data, comorbidities,
clinical presentation, vital signs and the need for hospital
admission were recorded.
Once DVI was suspected, blood samples were col-
lected and tested for detection of DV-specific IgM/IgG
and NS1 antigen (Fig. 2). Additionally, hemoglobin,
hematocrit, white blood cell and platelets count were
performed (XS-1000i™; Sysmex Roche®, Kobe, Japan).
Patients with confirmed DVI and arterial hypotension
[systolic blood pressure (SBP) <90 mmHg], fever
(temperature >37.8 °C), tachycardia [heart rate (HR)
>100 bpm) and/or hemoconcentration (hematocrit >50%
for men or >48% for women) were admitted for intra-
venous (I.V.) fluid administration and/or symptomatic
support (Fig. 2). In 53 patients with confirmed DVI and
Fig. 1 Patients’ flow diagram
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thrombocytopenia (platelet count <100 x 109/L), conven-
tional coagulation tests (PT, TT, INR and aPTT) (STA
Compact; Stago®, Asnières-sur-Seine, France), serum fi-
brinogen level (Clauss method) (STA Compact; Stago®,
Asnières-sur-Seine, France), plasma d-dimer level (STA
Compact; Stago®, Asnières-sur-Seine, France) and rota-
tional thromboelastometry (ROTEM®; Pentapharm Co.,
Munich, Germany) were performed.
Thromboelastometry
Thromboelastometry (ROTEM) assesses the viscoelastic
properties of the clot and provides information on the
speed of coagulation initiation, kinetics of clot forma-
tion, clot strength and breakdown [14, 15]. Blood sam-
ples of 3 ml were collected in citrate tubes (3.2%;
Sarsted®, Wedel, Germany) and processed within a
period of three hours for thromboelastometry analysis.
The analyses were performed by pipetting 300 μl of
citrated whole blood and 20 μl of 0.2 M calcium chloride
with specific activators into a plastic cup [16]. Measure-
ment of coagulation in ROTEM was performed after the
vertical immersion of a plastic pin into the blood sample.
The pin rotates slowly backwards and forwards through
an angle of 4.75°. By generation of the first fibrin fila-
ments between the pin and the wall of the test cup, the
rotational range of the pin is reduced [13]. The increased
restriction of the pin’s movement is transferred to a
graphical display, a plot that shows changes in the visco-
elastic properties of the clot over time [15].
The following parameters were recorded during
ROTEM analysis: clotting time [CT; seconds (sec)],
which represents the beginning of the test until a clot
firmness of 2 mm is detected, clot formation time (CFT;
sec), until a clot firmness of 20 mm has been reached,
alpha angle (degrees) represents the slope (tangent) be-
tween a CT of 2 mm and CFT of 20 mm, amplitude 10
(A10; mm), which represents the clot amplitude 10 min
after the beginning of clotting and maximum clot firm-
ness (MCF; mm), which represents the greatest ampli-
tude of the thromboelastometric trace and reflects the
“strength” of the clot [13–16]. We performed an extrin-
sically activated thromboelastometric test (EXTEM), a
test that uses rabbit brain thromboplastin as an activa-
tor; an intrinsically activated thromboelastometric test
(INTEM), a test that uses ellagic acid as an activator and
a fibrin-based thromboelastometric test (FIBTEM), a test
that assesses the fibrin-based clot using both extrinsic
activation and addition of cytochalasin D to inhibit
platelets’ contribution to clot formation [13, 15].
Impaired ROTEM (hypocoagulability) was defined as a
clot formation speed above the upper limit of the refer-
ence interval (CT INTEM >246 s or CT EXTEM >74 s)
Fig. 2 Patient’s flow chart attendance during dengue virus infection outbreak. Legend: 1: blood samples for detection of dengue virus specific
IgM/IgG and NS1 antigen, hemoglobin, hematocrit, white blood cell and platelet count. 2: in the 53 patients with confirmed dengue virus
infection and thrombocytopenia (platelet count <100 x 109/L), conventional coagulation tests (PT, TT, INR and aPTT), serum fibrinogen level,
plasma d-dimer levels and rotational thromboelastometry (ROTEM®) were performed
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and/or (CFT INTEM >100 s or CFT EXTEM >148 s)
and/or a MCF below the lower limit of the reference
interval (INTEM MCF <52 mm or EXTEM MCF
<49 mm) and/or alpha angle below the lower limit of
the reference interval (INTEM alpha angle <70° or
EXTEM alpha angle <63°) [13, 15]. Finally, impaired
ROTEM on FIBTEM was defined as a MCF <9 mm
[16]. Normal ROTEM was considered if CT, CFT, MCF
and alpha angle were within the reference ranges
(INTEM CT: 137–246 s, CFT: 40–100 s, alpha angle:
70–83° and MCF: 52–72 mm; EXTEM CT: 42–74 s,
CFT: 46–148 s, alpha angle: 63–83° and MCF: 49–
71 mm; FIBTEM MCF: 9–25 mm) [15, 16].
Statistical analysis
Categorical variables were presented as absolute and
relative frequencies. Continuous variables were pre-
sented as mean values and standard deviation (SD) or
median values with interquartile ranges (IQR) in case of
non-normal distribution (tested by the Kolmogorov-
Smirnov test). Continuous variables were compared
using independent t test or Mann–Whitney U test in
case of non-normal distribution.
Two-tailed tests were used and when p < 0.05, the test
was considered statistically significant. The SPSS™ (IBM
SPSS Statistics for Windows, Version 21.0. Armonk, NY:
IBM Corp) and GraphPad Prism version 6.0 (GraphPad
Software, La Jolla, California, USA) were used for statis-
tical analyses.
Results
From April 6th to May 5th 2015, 4641 medical appoint-
ments were scheduled at the outpatient clinic. From
those, 3003 were first consultations (Fig. 1). Dengue
virus infections were confirmed in 68.9% (2069/3003) of
patients while 10.8% (224/2069) of patients had DVI and
thrombocytopenia. Out of those, fifty-three patients [53/
224 (23.6%)] were consecutively enrolled in this study
(Fig. 1).
The main characteristics of DVI patients included in
this study are shown in Table 1. The median age of DVI
patients was 32 (IQR, 21–43) years and approximately
60% were male. The majority of DVI patients [31/42
(73.8%)] had no significant previous medical history.
Most DVI patients presented with fever and headache
and were hemodynamically stable (Table 1). Onset of
symptoms was acute (median, 4 days; IQR, 2–5), which
is consistent with predominance of NS1 positive results
[51/53 (96.2%)]. Bleeding manifestations such as epi-
staxis, gingivorrhagia, hematemesis, hematuria and
melena were reported in only 14.3% (7/49) of patients
(Table 1). A total of 5.8% (3/52) of patients required
hospitalization.
Laboratorial characteristics
The main laboratorial characteristics of DVI patients are
shown in Table 2. All DVI patients with thrombocytopenia
[median (IQR) platelets count: 76 (62–88) x109/L] had
normal coagulation tests such as PT, TT, INR and aPTT
(Table 2).
Thromboelastometry
The INTEM and EXTEM analysis were abnormal in, re-
spectively, 71.7% (38/53) and 54.7% (29/53) of DVI pa-
tients while FIBTEM was normal in 94.3% (50/53) of
DVI patients (Table 3). DVI patients with impaired
Table 1 Main characteristics of participating patients. Values
represent % (n/total) or median (interquartile range [IQR])
Characteristics Valuesa
Age, years 32 (21–43)
Gender, male 60.4 (32/53)
Comorbidities
None 73.8 (31/42)
Hypertension 16.7 (7/42)
HIV infection 2.4 (1/42)
Prostatic hyperplasia 4.8 (2/42)
Dyspepsia 2.4 (1/42)
Clinical presentation
Fever 100.0 (53/53)
Headache 83.0 (44/53)
Rash 36.8 (14/38)
Vomiting 25.5 (13/51)
Bleeding manifestationsb 14.3 (7/49)
Dehydrationc 11.3 (6/53)
Axillary temperature 37.0 (36.1-37.7)
Systolic blood pressure 127 (115–133)
Diastolic blood pressure 80 (73–86)
Heart rate 93 (82–102)
Serologic diagnosis
NS1 96.2 (51/53)
IgM 20.8 (11/53)
IgG 3.8 (2/53)
Prior DV infectiond 9.8 (5/51)
Yellow Fever vaccinatione 18.9 (7/37)
Days after onset of symptoms 4 (2–5)
Need of hospitalizationf 5.8 (3/52)
HIV Human Immunodeficiency Virus, NS1 non-structural protein-1, IgM
Immunoglobulin M, IgG Immunoglobulin G; a Totals may not sum to 53,
owing to missing values; b epistaxis, gingivorrhagia, hematemesis,
hematuria and melena; c clinical signs in mucosa and skin assessed by
medical attendant; d considered if patient acknowledge a prior diagnosis stated
by medical service. e: considered if patient acknowledge as a positive previous
vaccination status, f: Unknown in one patient (lost to follow-up)
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(hypocoagulability) ROTEM in INTEM and EXTEM as-
says exhibited higher CFT, lower MCF and alpha angle
than DVI patients with a normal ROTEM (Table 3).
Hypocoagulability was found in 28.6% (2/7) of DVI pa-
tients with minor bleeding manifestations in EXTEM
and in 57.1% (4/7) patients in INTEM. Out of three pa-
tients who required hospitalization, two (66.6%) exhib-
ited hypocoagulability in INTEM and one (33.3%) on
EXTEM.
Conventional coagulation tests versus
thromboelastometry
Comparisons between thromboelastometry and conven-
tional coagulation tests are shown in Table 4. Compared
to DVI patients with normal INTEM, DVI patients pre-
senting with impaired INTEM exhibited lower platelet
count, INR and plasma fibrinogen levels (Table 4). Den-
gue virus infection patients presenting with impaired
EXTEM exhibited lower plasma fibrinogen levels and
higher d-dimer, while platelets count, INR and aPTT did
not differ between the groups (Table 4). Finally,
Table 2 Laboratory and conventional coagulation tests result in
dengue virus infection patients. Values are presented as median
and interquartile range
Characteristics
Hemoglobin (g/dL) 15.1(14.2-16.1)
Hematocrit (%) 42.9 (40.6-45.6)
White Blood Cells (x103/uL) 3.1 (2.7-4.5)
Neutrophil (%) 42.3 (31.0-48.0)
Neutrophil (x103/uL) 1.4 (1.0-1.8)
Platelets (x 109/L) 76 (62–88)
Prothrombin time (sec) 100 (90–100)
INR 1.0 (1.0-1.1)
Thrombin Time (sec) 18.2 (17.0-19.5)
aPTT (sec) 28.9 (26.0-32.5)
Fibrinogen (g/dl) 290 (267–323)
D-dimer (ng/ml) 1330 (800–1840)
INR international normalized ratio, aPTT activated partial thromboplastin time
Table 3 Rotational thromboelastometry (ROTEM®) parameters in dengue virus infection patients. Values represent median (IQR)
Characteristics All Normal Impaired P value*
INTEM, % (n/total) 100.0 (53/53) 28.3 (15/53) 71.7 (38/53)
Clotting time (sec) 177 (160–207) 166 (158–179) 180 (161–214) 0.114b
Clot formation time (sec) 144 (108–178) 98 (90–106) 166 (131–220) <0.001b
Maximum clot firmness (mm) 48 (42–52) 53 (52–55) 45 (41–49) <0.001a
Alpha angle (degrees) 69 (63–73) 74 (72–74) 66 (62–69) <0.001a
Amplitude 10 (mm) 41 (37–45) 48 (47–50) 37 (33–42) <0.001a
EXTEM, % (n/total) 100.0 (53/53) 45.3 (24/53) 54.7 (29/53)
Clotting time (sec) 69 (65–78) 68 (61–74) 74 (66–84) 0.044a
Clot formation time (sec) 148 (126–198) 126 (114–140) 197 (163–269) <0.001b
Maximum clot firmness (mm) 49 (44–55) 54 (52–56) 44 (40–48) <0.001a
Alpha angle (degrees) 68 (63–72) 72 (68–74) 65 (56–69) <0.001b
Amplitude 10 (mm) 41 (35–46) 46 (44–48) 36 (31–39) <0.001a
FIBTEM, % (n/total) 100.0 (53/53) 94.3 (50/53) 5.7 (3/53)
Maximum clot firmness (mm) 15 (13–18) 16 (14–18) 7 (7–8) 0.004b
*: Comparisons between normal and impaired groups. p values with (a) independent t test and (b) Mann–Whitney U test
Table 4 Rotational thromboelastometry (ROTEM®) analysis and
conventional coagulation tests. Values represent median (IQR)
Characteristics Normal Impaired P value
INTEM, % (n/total) 28.3 (15/53) 71.7 (38/53)
Platelets (x 109/L) 90 (77–94) 70 (57–84) 0.005a
INR 1.1 (1.0-1.3) 1.0 (1.0-1.1) 0.034b
aPTT (sec) 28.2 (26.0-31.8) 29.0 (26.0-33.3) 0.867b
Fibrinogen (g/dl) 321 (290–355) 278 (267–311) 0.021b
D-dimer (ng/ml) 950 (320–1510) 1410 (950–1900) 0.076b
EXTEM, % (n/total) 45.3 (24/53) 54.7 (29/53)
Platelets (x 109/L) 82 (68–91) 69 (57–83) 0.052a
INR 1.0 (1.0-1.1) 1.0 (1.0-1.1) 0.390b
aPTT (sec) 30.3 (25.0-32.2) 28.1 (26.6-32.8) 0.816b
Fibrinogen (g/dl) 308 (278–354) 278 (264–300) 0.006a
D-dimer (ng/ml) 950 (705–1500) 1600 (1220–1990) 0.008b
FIBTEM, % (n/total) 94.3 (50/53) 5.7 (3/53)
Platelets (x 109/L) 77 (62–88) 71 (64–95) 0.758b
INR 1.0 (1.0-1.1) 1.1 (1.0-1.1) 0.427b
aPTT (sec) 28.5 (26.0-31.8) 33.3 (26.7-33.4) 0.254b
Fibrinogen (g/dl) 291 (267–323) 278 (214–315) 0.520b
D-dimer (ng/ml) 1295 (790–1820) 1840 (1500–1980) 0.223b
INR international normalized ratio and aPTT activated partial thromboplastin
time. p values with (a) independent t test and (b) Mann–Whitney U test
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conventional coagulation tests did not differ between
DVI patients with normal or abnormal FIBTEM
(Table 4).
Discussion
This study demonstrated that DVI patients with
thrombocytopenia frequently exhibited hypocoagulability
assessed by thromboelastometry while conventional co-
agulation tests (PT, TT, INR and aPTT) and plasma fi-
brinogen levels remained within reference range.
Our findings contrasted previous retrospective stud-
ies, which demonstrated that prolonged coagulation
times are frequent and strongly associated with bleed-
ing manifestations in DVI thrombocytopenic patients
[8, 9, 17, 18]. For instance, Wills and colleagues dem-
onstrated in DHF Vietnamese children that a pro-
longed aPTT >30 s and platelet count <50 x 109/L
had an increased risk of bleeding [9]. They also sug-
gested that thrombocytopenia is a mortality predictor
in this population of patients [9]. The discrepancy be-
tween our findings and those reported by others
could be explained, at least in part, by the differences
in severity among DVI studied patients [2, 4].
Bleeding complications in DVI patients have been as-
sociated with a combination of thrombocytopenia, re-
duced thrombin formation and increased fibrinolysis
[19, 20]. According to Nimmannitya, even extremely low
platelet count, such as <20 x 109/L, does not increase
bleeding risk except in prolonged shock states [21]. This
is a very interesting observation since DVI patients fre-
quently exhibited low platelets in association with im-
paired platelets function [4, 7, 19]. Platelets are crucial
for primary hemostasis as they contribute to thrombus
formation [10, 22]. Fibrinogen, the final substrate of co-
agulation and the ligand of platelet glycoprotein IIb-IIIa
complex receptors, enhance platelets function [10, 16].
Therefore, we can assume that the low frequency of
bleeding manifestations in thrombocytopenic DVI pa-
tients in our study can be explained, at least in part, by
maintained plasma fibrinogen levels, as shown in FIB-
TEM analysis [13, 15].
It is likely that fibrinogen plays a key role in keeping
clot strength in DVI patients during the first days of dis-
ease [10, 20, 22]. Fibrinogen, the factor I of coagulation
system, is the most important numerically and function-
ally coagulation factor [12, 22]. Fibrinogen represents
approximately ninety percent of the total amount of
plasmatic coagulation factors and it is the first coagu-
lation factor to fall below a critical value during
bleeding and hemodilution [10, 20, 22, 23]. Neverthe-
less, the critical plasma fibrinogen level associated to
increased severity of DVI patients due to major bleed-
ing events, hospitalization and death, needs to be
determined [3, 4, 9, 20].
Disseminated intravascular coagulation (DIC) is defined
by the presence of four criteria: thrombocytopenia (plate-
lets below 100 x109/L), high level of products of fibrin
degradation (PDF), such as d-dimer, PT prolongation and
low plasma fibrinogen level [24]. Our study demonstrated
that patients in the first days of DVI already met at least
two out of four criteria for DIC (low platelets and high
PDF). Studies addressing hemostasis in DHF patients
showed that all DHF patients manifested acute type of
DIC [19, 20, 25]. Prolongation of aPTT and PT, decreased
platelets count, plasma fibrinogen level, prothrombin, fac-
tor VIII, plasminogen and antithrombin III activities were
observed transiently during acute phase of DHF [9, 20, 25]
and they characterize hemorrhagic diathesis of DVI severe
patients [3, 4, 20, 21, 25].
Viscoelastic tests allow early and individualized coagula-
tion management in different scenarios, such as in trauma
[26, 27], liver transplantation [13, 28], cardiac [15, 28] and
neurologic surgeries [16, 29], post-partum hemorrhage
[12, 27] and in critically ill patients [22, 26, 28]. Neverthe-
less, dengue treatment is based mainly on supportive care
with fluids and electrolytes [2, 4, 30, 31]. Transfusion trig-
gers and therapeutic goals are not consensus in DVI pa-
tients [2, 5, 30, 31]. A report of four DVI bleeding patients
with severe DVI and thrombocytopenia in which desmo-
pressin were administrated, showed clinical improvement
and hemorrhage control [32]. Desmopressin is a hormone
that stimulates release of Von Willebrand factor (vWF) by
endothelial cells [10, 22]. The complex factor VIII (FVIII)
and vWF improve platelets aggregation and clot stability
[33]. Increased levels of vWF were demonstrated in DVI
patients during the first days of disease [19, 33]. FVIII/
vWF complex is likely to play a key hemostatic role during
the early course of DVI [10, 22]. Endothelial activation
may be responsible for extravascular plasma leakage and
shock in severe DVI patients [2–5]. However, in the ma-
jority of DVI patients, inflammation and endothelial cell
activation may represent a compensatory mechanism for
thrombocytopenia, clot impairment and hypocoagulability
during the early course of disease due to fibrinogen activa-
tion and increased vWF levels, which improve platelet
aggregation [33–35].
Another key point in the treatment of DVI patients
is the need of high I.V. volume expansion due to in-
tense plasma leakage [2, 30, 31]. Thus, dilution coag-
ulopathy may be present in DVI patients and further
aggravate coagulation [2, 22, 34]. A thromboelastome-
try study showed clot impairment after fluid challenge
infusions [36]. A fibrin polymerization deficit is as-
sumed to be one of the major side effects of colloids
and crystalloids on coagulation. However, impaired
coagulation due to dilution coagulopathy is usually
transient and can be partially reversed by fibrinogen
concentrate transfusion [10, 36]. Moreover, colloids
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can also impair thrombus generation [22], decrease
factor XIII-fibrin polymer interaction [36] and de-
crease platelet aggregability and adhesion [10, 11].
This could perpetuate a vicious circle of clot impair-
ment in DVI patients with hypocoagulability second-
ary to a viral infection [37]. Therefore, we need to
keep in mind the importance of individualizing
volume expansion in DVI patients presenting with co-
agulopathy [31–34]. Therefore, a thromboelastometry-
driven approach could represent an alternative
strategy to manage complex cases of DVI associated
with coagulopathy [37–39].
Our study has limitations. First, a small sample of DVI
patients was included in this analysis. Nevertheless, to
our knowledge, this was the first time DVI patients were
analyzed with viscoelastic test such as thromboelastome-
try. Furthermore, most patients included in this report
had primary DVI and were not severely ill, which might
have affected and/or ameliorated their conventional co-
agulation tests results. Second, conventional coagulation
tests abnormalities and bleeding disorders could be
more pronounced in later stages during the course of
disease and therefore not detected by our study. Third,
dengue virus infection was confirmed by using immuno-
chromatographic assays, which may lack sensitivity and
specificity compared to real time polymerase chain reac-
tion (PCR) or enzyme-linked immunosorbent assays
(ELISA) for detection of IgM/IgG antibodies and NS1
antigen [40]. Finally, although Zika and Chikungunya vi-
ruses co-infections are well known today, they were un-
known when this study was conducted [41]. Since
diagnostic tools for Zika virus infection were not avail-
able in Brazil when the study was carried out, we cannot
rule out Zika virus co-infection in our studied patients.
Conclusion
Outpatients with dengue virus infection and
thrombocytopenia commonly exhibited impaired throm-
boelastometry despite normal conventional coagulation
tests. That suggests viscoelastic tests might have a higher
sensitivity to detect early coagulation abnormalities in
this population of patients. Long-term outcomes and the
question of whether or not transfusion resuscitation al-
gorithms based on viscoelastic tests will improve out-
comes in DVI patients with coagulopathy and bleeding
needs to be further evaluated.
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